A Maltese menopause expert is likely feeling vindicated after the US FDA announced plans to remove black-box warnings from hormone replacement therapy (HRT) products used to treat menopause symptoms. The FDA’s decision follows a comprehensive review of scientific evidence and an expert panel discussion, acknowledging that previous warnings were based on outdated research. The shift in stance recognizes that HRT can be safe and effective for women, particularly when initiated within 10 years of menopause onset and tailored to individual needs.
The removal of black-box warnings is expected to improve access to HRT, addressing concerns that previous warnings deterred women from seeking treatment. The FDA also approved two new menopause treatments, including a generic version of Premarin, aiming to increase affordability and accessibility. This development may encourage more women to discuss HRT options with their healthcare providers, promoting informed decision-making.
